Table 2.
Baseline Characteristics by Molecular Subgroups
| Differentiated (N=73) |
Immunoreactive (N=122) |
Mesenchymal (N=68) |
Proliferative (N=96) |
Total (N=359) |
|
|---|---|---|---|---|---|
| Treatment | |||||
| Bevacizumab | 36 (49.3%) | 69 (56.6%) | 37 (54.4%) | 47 (49.0%) | 189 (52.6%) |
| Standard | 37 (50.7%) | 53 (43.4%) | 31 (45.6%) | 49 (51.0%) | 170 (47.4%) |
| Age (years) at randomization | |||||
| Mean (SD) | 52.0 (12.9) | 57.0 (9.8) | 59.5 (11.3) | 62.0 (9.1) | 57.8 (11.1) |
| Range | (21.0–75.0) | (35.0–77.0) | (21.0–80.0) | (37.0–80.0) | (21.0–80.0) |
| Race | |||||
| White | 73 (100.0%) | 122 (100.0%) | 65 (95.6%) | 96 (100.0%) | 356 (99.2%) |
| Asian | 0 (0.0%) | 0 (0.0%) | 3 (4.4%) | 0 (0.0%) | 3 (0.8%) |
| ECOG score | |||||
| 0 | 29 (39.7%) | 64 (52.5%) | 23 (33.8%) | 39 (40.6%) | 155 (43.2%) |
| 1 | 38 (52.1%) | 45 (36.9%) | 42 (61.8%) | 51 (53.1%) | 176 (49.0%) |
| 2 | 6 (8.2%) | 13 (10.7%) | 3 (4.4%) | 6 (6.3%) | 28 (7.8%) |
| Origin of cancer | |||||
| Ovary | 73 (100.0%) | 105 (86.1%) | 57 (83.8%) | 84 (87.5%) | 319 (88.9%) |
| Primary peritoneal | 0 (0.0%) | 8 (6.6%) | 8 (11.8%) | 8 (8.3%) | 24 (6.7%) |
| Fallopian tube | 0 (0.0%) | 7 (5.7%) | 3 (4.4%) | 4 (4.2%) | 14 (3.9%) |
| Multiple sites | 0 (0.0%) | 2 (1.6%) | 0 (0.0%) | 0 (0.0%) | 2 (0.6%) |
| Histology | |||||
| Serous | 53 (72.6%) | 91 (74.6%) | 56 (82.4%) | 77 (80.2%) | 277 (77.2%) |
| Clear cell | 5 (6.8%) | 5 (4.1%) | 3 (4.4%) | 1 (1.0%) | 14 (3.9%) |
| Endometrioid | 3 (4.1%) | 2 (1.6%) | 1 (1.5%) | 4 (4.2%) | 10 (2.8%) |
| Mucinous | 1 (1.4%) | 1 (0.8%) | 3 (4.4%) | 0 (0.0%) | 5 (1.4%) |
| Mixed | 9 (12.3%) | 13 (10.7%) | 3 (4.4%) | 11 (11.5%) | 36 (10.0%) |
| Other | 2 (2.7%) | 10 (8.2%) | 2 (2.9%) | 3 (3.1%) | 17 (4.7%) |
| FIGO stage | |||||
| I/IIA | 8 (11.0%) | 8 (6.6%) | 3 (4.4%) | 7 (7.3%) | 26 (7.2%) |
| IIB/IIC | 10 (13.7%) | 8 (6.6%) | 1 (1.5%) | 4 (4.2%) | 23 (6.4%) |
| III | 44 (60.2%) | 91 (73.7%) | 50 (73.6%) | 66 (68.7%) | 251 (69.8%) |
| IV | 11 (15.1%) | 15 (12.3%) | 14 (20.6%) | 19 (19.8%) | 59 (16.4%) |
| Grade | |||||
| 1 or 2 | 28 (38.9%) | 16 (13.3%) | 15 (22%) | 15 (15.8%) | 74 (20.8%) |
| 3 | 44 (61.1%) | 104 (86.7%) | 53 (77.9%) | 80 (84.2%) | 281 (79.2%) |
| Missing | 1 | 2 | 0 | 1 | 4 |
| Outcome of surgery | |||||
| Optimal (< 1cm residual tumor) | 59 (80.8%) | 99 (81.1%) | 48 (70.6%) | 68 (70.8%) | 274 (76.3%) |
| Sub-Optimal (>1cm residual tumor) | 13 (17.8%) | 22 (18.0%) | 20 (29.4%) | 28 (29.2%) | 83 (23.1%) |
| Inoperable | 1 (1.4%) | 1 (0.8%) | 0 (0.0%) | 0 (0.0%) | 2 (0.6%) |
| High-risk of progression* | |||||
| No | 55 (75.3%) | 90 (73.8%) | 39 (57.4%) | 56 (58.3%) | 240 (66.9%) |
| Yes | 18 (24.7%) | 32 (26.2%) | 29 (42.6%) | 40 (41.7%) | 119 (33.1%) |
*
High risk of progression suboptimal debulked stage III, inoperable Stage III, all stage IV.